MaR1 reduces inflammation by reducing neutrophil and macrophage infiltration, activating Nrf2 signalling, and inactivating TLR4/NF-κB signalling. Besides, MaR1 improves TJ protein expression and decreases MPO and ROS activity, therefore ameliorating DSS-induced colitis. This evidence concerns the gene NFKB1 and colitis.